Evaluation of Clinical Utility of the Personal KinetiGraph® in the Management of Parkinson Disease

Fatta B. Nahab, Hamad Abu-Hussain, L. Moreno
{"title":"Evaluation of Clinical Utility of the Personal KinetiGraph® in the Management of Parkinson Disease","authors":"Fatta B. Nahab, Hamad Abu-Hussain, L. Moreno","doi":"10.4236/apd.2019.83005","DOIUrl":null,"url":null,"abstract":"INTRODUCTION: Parkinson’s disease (PD) is a \ndisorder characterized by complex motor and non-motor symptoms that can be \ndifficult for patients to accurately communicate. Wearable technologies portend \nimprovements in assessment and monitoring of these symptoms, with their \nclinical utility currently being evaluated in routine clinical care. OBJECTIVE: \nTo evaluate the clinical utility of the Personal \nKinetiGraph? (PKG?) Movement Recording System in the routine \nclinical care of persons with PD (PWP). METHODS: Clinically stable, \nnon-demented PWP presented for two routine clinic visits that included: \nmedication review, symptom review, neurological examination including the \nMovement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) \nIII/IV, and completion of a clinical management plan by a movement disorder \nspecialist prior to review of the PKG report. After reviewing the PKG report, \nthe clinician completed a modified clinical management plan taking into \nconsideration the findings of the PKG. This was repeated at a second visit to evaluate \nvarious outcome measures following PKG-enhanced management. RESULTS: The PKG \nimproved the assessment of PD symptoms and the response to treatment, while \nincreasing patient activity levels and compliance. Clinical management plans \nenhanced by PKG led to different recommendations in 29.4% of cases compared \nwith standard of care due to higher rates of bradykinesia, dyskinesia, tremor, \nand fluctuations identified by PKG. Using the PKG in the clinical management \nplan led to a change in medications in 75% (21/28) of patients and both a \nstatistically significant difference and a clinically meaningful reduction in \nMDS-UPDRS III score of 4.8 (p = 0.028). Additionally, positive changes in both \nthe clinician (17/28; 61%) and patient-reported (13/24; 54%) Global Impression \nof Improvement were reported. CONCLUSION: The PKG is a valuable tool in \naugmenting clinical management when utilized along with a clinical assessment.","PeriodicalId":7350,"journal":{"name":"Advances in Parkinson's Disease","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Parkinson's Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/apd.2019.83005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

Abstract

INTRODUCTION: Parkinson’s disease (PD) is a disorder characterized by complex motor and non-motor symptoms that can be difficult for patients to accurately communicate. Wearable technologies portend improvements in assessment and monitoring of these symptoms, with their clinical utility currently being evaluated in routine clinical care. OBJECTIVE: To evaluate the clinical utility of the Personal KinetiGraph? (PKG?) Movement Recording System in the routine clinical care of persons with PD (PWP). METHODS: Clinically stable, non-demented PWP presented for two routine clinic visits that included: medication review, symptom review, neurological examination including the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) III/IV, and completion of a clinical management plan by a movement disorder specialist prior to review of the PKG report. After reviewing the PKG report, the clinician completed a modified clinical management plan taking into consideration the findings of the PKG. This was repeated at a second visit to evaluate various outcome measures following PKG-enhanced management. RESULTS: The PKG improved the assessment of PD symptoms and the response to treatment, while increasing patient activity levels and compliance. Clinical management plans enhanced by PKG led to different recommendations in 29.4% of cases compared with standard of care due to higher rates of bradykinesia, dyskinesia, tremor, and fluctuations identified by PKG. Using the PKG in the clinical management plan led to a change in medications in 75% (21/28) of patients and both a statistically significant difference and a clinically meaningful reduction in MDS-UPDRS III score of 4.8 (p = 0.028). Additionally, positive changes in both the clinician (17/28; 61%) and patient-reported (13/24; 54%) Global Impression of Improvement were reported. CONCLUSION: The PKG is a valuable tool in augmenting clinical management when utilized along with a clinical assessment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
个人KinetiGraph®在帕金森病治疗中的临床应用评估
简介:帕金森病(PD)是一种以复杂的运动和非运动症状为特征的疾病,患者难以准确沟通。可穿戴技术预示着这些症状的评估和监测的改进,其临床应用目前正在常规临床护理中进行评估。目的:评价Personal KinetiGraph的临床应用价值?(包裹)运动记录系统在PD患者常规临床护理中的应用。方法:临床稳定,无痴呆的PWP进行两次常规门诊检查,包括:药物审查,症状审查,神经学检查,包括运动障碍学会统一帕金森病评定量表(MDS-UPDRS) III/IV,以及在审查PKG报告之前由运动障碍专家完成临床管理计划。在审查PKG报告后,临床医生根据PKG的发现完成了修改后的临床管理计划,并在第二次就诊时重复该计划,以评估PKG增强管理后的各种结果措施。结果:PKG改善了PD症状的评估和对治疗的反应,同时增加了患者的活动水平和依从性。由于PKG检测出的运动迟缓、运动障碍、震颤和波动率更高,与标准护理相比,经PKG增强的临床管理计划导致29.4%的病例推荐不同的药物。在临床管理计划中使用PKG导致75%(21/28)的患者改变药物治疗,统计学差异显著,MDS-UPDRS III评分降低4.8 (p = 0.028),具有临床意义。此外,临床医生(17/28;61%)和患者报告(13/24;54%)报告了改善的全球印象。结论:PKG与临床评估一起使用是加强临床管理的一种有价值的工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Contradiction between Traditional Chinese Medicine and Modern Medicine in Understanding and Treating Parkinson’s Disease and Its Solutions Effects of COVID-19 on Outpatient Visitation of Japanese Parkinson’s Disease and Parkinsonism Patients Receiving Rehabilitation Effect of Varenicline on Detrusor Overactivity in Rat Model of Parkinson’s Disease Induced by Intranigral 6-Hydroxydopamine DJ-1 Activation Raf/ERK Pathways Promotes Autophagy Maturation of PC-12 Cells Can We Use Consumer-Wearable Activity Tracker Fitbit in Parkinson Disease?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1